# Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma

> **NCT03168607** · PHASE2 · UNKNOWN · sponsor: **Peking University** · enrollment: 45 (estimated)

## Conditions studied

- Neuroendocrine Carcinoma

## Interventions

- **DRUG:** FOLFIRI Protocol

## Key facts

- **NCT ID:** NCT03168607
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05-02
- **Primary completion:** 2019-05-02
- **Final completion:** 2020-05-02
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2017-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03168607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03168607, "Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03168607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*